Evidence map›Paper›PMID 40535089›Full record

ArticleTranslational lung cancer research2025

Visceral crisis in a patient with non-small cell lung cancer and

Vaneza Avila Rodriguez, Nicolle Wagner-Gutiérrez, Jairo Andrés Zuluaga León, Leonardo Rojas, Lucia Viola, Stella Isabel Martínez Jaramillo, Carlos Andrés Carvajal Fierro, Alejandro Ruiz-Patiño, Oscar Arrieta, Luis Corrales and 2 more

Abstract readCase Reports
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vaneza Avila RodriguezThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0002-0050-6883
Nicolle Wagner-GutiérrezUniversity of North Carolina at Chapel Hill, School of Global Public Health, Chapel Hill, NC, USA.ORCID https://orcid.org/0000-0002-2015-1901
Jairo Andrés Zuluaga LeónThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
Leonardo RojasThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0002-7865-5424
Lucia ViolaThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0002-1647-2884
Stella Isabel Martínez JaramilloThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0002-4376-7119
Carlos Andrés Carvajal FierroThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0001-5915-0052
Alejandro Ruiz-PatiñoThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0003-1274-9273
Oscar ArrietaThoracic Oncology Unit, National Cancer Institute-INCaN, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-1164-3779
Luis CorralesLatin American Consortium for Lung Cancer Research, CLICaP.ORCID https://orcid.org/0000-0001-9732-5693
Claudio MartinLatin American Consortium for Lung Cancer Research, CLICaP.ORCID https://orcid.org/0000-0003-4135-7332
Andrés F CardonaThoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID https://orcid.org/0000-0003-3525-4126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Case Description: We report a unique case of early entrectinib resistance due to a gatekeeper mutation in the ROS1 kinase domain, underscoring the importance of molecular profiling in optimizing therapeutic strategies. We report a case of a 50-year-old male, a non-smoker, who was diagnosed with ROS1-rearranged NSCLC harboring an Conclusions: The emergence of the L2026M mutation suggests a need for next-generation TKIs and combination strategies to overcome resistance. Future studies should explore novel inhibitors targeting ROS1 resistance pathways to improve outcomes in this subset of NSCLC patients.

Indexed as

case reportentrectinibL2026MResistance mechanismROS1::SDC4 fusion

Identifiers

PMID40535089
PMCPMC12170252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.